GlassScriptPhysician profile
Sreekanth C Reddy
NPI 1437199965
$115,997.59
in general payments reported to CMS, 2019-2025
78 companies · $16K in 2025
The $16K reported for 2025 was more than what 85% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $5,065 · 2021: $6,718 · 2022: $5,429 · 2023: $31K · 2024: $18K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $18K · Food and Beverage: $14K · Travel and Lodging: $1,975 · Honoraria: $1,088 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,155.50 |
| Consulting Fee | $17,895.50 |
| Food and Beverage | $13,960.70 |
| Travel and Lodging | $1,974.61 |
| Honoraria | $1,088.00 |
| Education | $404.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $19,774.71 | 2019-2020 | |
| Seagen INC. | $15,546.81 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Astellas Pharma US INC | $12,560.21 | 2020-2025 | Padcev, Xtandi, Cresemba |
| Celgene Corporation | $10,732.27 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Genzyme Corporation | $9,265.57 | 2022-2025 | |
| Pfizer INC. | $7,662.86 | 2019-2025 | |
| Coherus Oncology, INC. | $7,060.33 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $5,561.02 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $5,266.79 | 2023-2025 | Cosela, Monoferric |
| Abbvie INC. | $2,485.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,193.75 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Genentech USA, INC. | $1,979.26 | 2019-2025 | Tecentriq, Rozlytrek, Alecensa |
| E.R. Squibb & Sons, L.L.C. | $1,730.10 | 2020-2025 | Opdivo, Reblozyl, Opdualag |
| Cti Biopharma Corp. | $1,465.68 | 2022 | |
| Merck Sharp & Dohme LLC | $1,347.86 | 2019-2025 | Keytruda, Welireg, Lynparza |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $1,244.48 | 2022-2025 | Tavalisse, Rezlidhia, Gavreto |
| Exelixis INC. | $1,060.62 | 2019-2025 | Cabometyx |
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $734.18 | 2019-2025 | |
| Janssen Biotech, INC. | $573.88 | 2019-2025 | Darzalex, Rybrevant, Carvykti |
| Eisai INC. | $433.78 | 2022-2025 | |
| Daiichi Sankyo INC. | $422.76 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Medtronic, INC. | $420.00 | 2021 | |
| Glaxosmithkline, LLC. | $384.98 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $383.14 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Stemline Therapeutics INC. | $291.16 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $287.49 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $268.16 | 2022-2025 | Trodelvy |
| Incyte Corporation | $245.81 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Puma Biotechnology, INC. | $217.77 | 2022-2025 | |
| Amgen INC. | $198.58 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Jazz Pharmaceuticals INC. | $196.29 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $183.25 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $148.21 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Servier Pharmaceuticals LLC | $145.54 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $137.30 | 2023-2025 | Xpovio |
| Adc Therapeutics America, INC. | $135.37 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $135.23 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Pharmacyclics LLC, An Abbvie Company | $135.06 | 2022-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $121.48 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $115.88 | 2019-2024 | Onivyde, Somatuline Depot |
| Thd America, INC. | $112.96 | 2019 | |
| Tersera Therapeutics LLC | $112.83 | 2022-2025 | Zoladex, Xermelo |
| Alexion Pharmaceuticals, INC. | $93.60 | 2019-2025 | Ultomiris |
| Adaptive Biotechnologies Corporation | $92.94 | 2024-2025 | Clonoseq |
| Geron Corporation | $88.00 | 2025 | Rytelo |
| Foundation Medicine, INC. | $81.56 | 2023 | Foundationone Liquid Cdx |
| Array Biopharma INC | $81.09 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Sobi, INC | $80.86 | 2024 | |
| Dendreon Pharmaceuticals LLC | $80.02 | 2023 | Provenge |
| G1 Therapeutics, INC. | $74.48 | 2022-2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $72.76 | 2023-2025 | Fotivda |
| Taiho Oncology, INC. | $68.67 | 2019-2024 | |
| Beigene USA, INC. | $62.75 | 2022-2024 | Brukinsa |
| Agios Pharmaceuticals, INC. | $57.23 | 2023-2025 | Pyrukynd |
| Myriad Genetic Laboratories, INC. | $53.91 | 2024-2025 | Myrisk |
| Eagle Pharmaceuticals, INC. | $53.54 | 2023 | |
| Pharmaessentia USA Corporation | $49.58 | 2023-2025 | Besremi |
| Azurity Pharmaceuticals, INC. | $47.03 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $44.80 | 2025 | Gomekli, Ogsiveo |
| Eusa Pharma (US) LLC | $39.97 | 2021-2022 | |
| Verastem, INC. | $36.38 | 2019 | |
| Epizyme, INC. | $35.88 | 2021 | |
| Fennec Pharmaceuticals, INC. | $23.36 | 2024 | Pedmark |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.35 | 2025 | |
| Morphosys, US INC. | $19.38 | 2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $19.17 | 2023 | Sylvant |
| Emd Serono, INC. | $17.90 | 2019 | |
| Global Blood Therapeutics, INC. | $17.37 | 2020 | |
| Dova Pharmaceuticals | $16.93 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.88 | 2019 | |
| Heron Therapeutics, INC. | $16.60 | 2022 | |
| Teleflex LLC | $16.17 | 2023 | Arrow |
| Shield Therapeutics INC | $14.70 | 2024 | |
| Octapharma USA, INC. | $14.13 | 2023 | Octagam Immune Globulin (Human) |
| Pharmaand Gmbh | $10.55 | 2025 | Rubraca |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreekanth Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.